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Summary
BACKGROUND: Post-transplant lymphoproliferative dis-
order (PTLD) is a potentially life-threatening complication
of transplantation occurring in the setting of immunosup-
pression and oncogenic viral infections. However, little is
known about the cumulative incidence, histological sub-
types, risk determinants and outcome of PTLD in solid or-
gan transplant (SOT) recipients in Switzerland.
METHODS: This retrospective observational study inves-
tigated adult SOT recipients from two sequential cohorts,
the pre-SCTS (Swiss Transplant Cohort Study) series,
with data collected from January 1986 to April 2008, and
the STCS series, with data collected from May 2008 to De-
cember 2014 in Switzerland. SOT recipients were cross-
referenced with the data of all the patients with a lym-
phoma diagnosis in each transplant centre and with the
data of the Swiss Transplant Cohort Study (STCS) to de-
termine the cumulative incidence of PTLD, pre-therapeu-
tic clinical features, clinical course and outcome. Kaplan-
Meier analysis was performed for overall survival after
PTLD.
RESULTS: We identified 79 cases of PTLD during the
study period in the two cohorts: pre-STCS from 1986 to
2008 (n = 62) and STCS from 2008 to 2014 (n = 17).
Histological subgroups included: early lesions (pre-STCS
n = 2, STCS n = 0); polymorphic PTLD (pre-STCS n =
8, STCS n = 7); monomorphic PTLD (pre-STCS n = 47,
STCS n = 10), and Hodgkin’s lymphoma (pre-STCS n
= 5, STCS n = 0). Median time to PTLD diagnosis was
90 months (range 3–281 months) and 14 months (range
2–59 months) in the pre-STCS and STCS cohorts, re-
spectively. Median follow-up after transplantation was 141
months for the pre-STCS patients and 33 months for the
STCS patients. Cumulative incidences of PTLD during the
STCS period at 0.5, 1 and 5 years were 0.17% (95% con-
fidence interval 0.07–0.46%), 0.22% (0.09–0.53%) and
0.96% (0.52–1.80%), respectively. For the pre-STCS case
series, it was not possible to estimate the incidence rate of
PTLD. Survival after PTLD diagnosis was 80% (68–87%)
at 1 year and 56% (42–68%) at 5 years for the pre-STCS
and STCS cohorts combined.
CONCLUSIONS: At 5 years, the cumulative incidence of
PTLD, regardless of the organ transplanted, was only
0.96% in the STCS cohort, which is lower than that report-
ed in the literature.
Key words: post-transplant lymphoproliferative disorder,
cumulative incidence, clinical features
Introduction
Solid organ transplant recipients have an elevated cancer
risk due to immunosuppression and subsequent oncogenic
viral infections [1]. Post-transplant lymphoproliferative
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disorder (PTLD) is a potentially life-threatening complica-
tion in up to 20% of transplanted patients [2], with non-
Hodgkin’s lymphoma accounting for 93% of cases [3].
PTLD development after solid organ transplantation is es-
timated to be from 1 to 20%, with the highest incidence for
intestinal and multivisceral transplants (up to 20%), fol-
lowed by lung and heart transplants (up to 10%), and the
lowest incidence for renal and liver transplants (up to 5%)
[4].
The pathogenesis of PTLD is based on the immunosup-
pression-associated reduction of CD8+ T cells responsible
for protective cytotoxic immunity to viruses [5], resulting
in an imbalance in Epstein-Barr virus (EBV)-positive B
cells, virus-specific cytotoxic T cells and regulatory T
cells. This facilitates the proliferation of EBV-positive B
cells and development of PTLD [6]. According to the
World Health Organization (WHO) classification 2008
(updated in 2016), PTLDs are subdivided into (a) early
lesions (plasmacytic hyperplasia, infectious mononucleo-
sis-like PTLD and florid follicular hyperplasia), (b) poly-
morphic PTLD (polyclonal lymphatic proliferations with
histoarchitectural tissue effacement), and (c) monomorphic
PTLD including B- and T-cell lymphoma resembling
PTLD and Hodgkin’s type of PTLD [6–8].
Since the likelihood of PTLD is strictly related to the de-
gree of immunosuppression and infection with EBV, pre-
vention is mainly achieved by limited patient exposure to
aggressive immunosuppressive regimens [9], rapid with-
drawal and tapering of agents required for graft tolerance,
and antiviral prophylaxis [10]. Options for initial treatment
of PTLD encompass reduction of immunosuppression
[11], immunotherapy with the anti-CD20 monoclonal anti-
body rituximab [12], chemotherapy [13], radiation therapy
[14], or a combination thereof.
Little is known about the outcome of PTLDs in Switzer-
land under treatment over time. We hypothesised that there
could be a difference in the cumulative incidence of
PTLDs between Switzerland and other countries, related to
differences in population, risk factors, management or ac-
cess to healthcare. For a better understanding and a useful
management of these disorders we conducted a retrospec-
tive study describing cumulative incidence, histological
subtypes, risk factors and outcome in our country.
Patients and methods
Patient identification
We conducted a retrospective evaluation of solid organ
transplant patients in Switzerland using two sequential co-
horts. A first case series before the Swiss Transplant Co-
hort Study, the pre-STCS cohort, started with data gathered
from PTLD patients in five transplant centres in Switzer-
land (Geneva University Hospital, Lausanne University
Hospital, Zurich University Hospital, Basel University
Hospital and St Gallen State Hospital) between January
1986 (date of transplantation) and April 2008. Only one
transplant centre in Switzerland did not participate in the
data gathering for the pre-STCS case series, which was not
expected to have changed significantly the final results.
The pre-STCS case series mostly cross-referenced the data
of solid organ transplant patients with the data of lym-
phoma patients diagnosed in each centre. Some data of
the pre-STCS case series were provided by Swiss Trans-
plant [15]. The data for the pre-STCS cohort were gathered
specifically for this study and were not in a national reg-
istry.
The second cohort, the Swiss Transplant Cohort Study
(STCS) [16] started in May 2008. The STCS covers solid
organ transplantation on a national scale in a complete and
comprehensive way. The last patient of this cohort includ-
ed in this study was diagnosed with PTLD in December
2014 Six percent of solid organ transplant patients nation-
wide did not give consent for their data to be included in
the STCS. Also, we lost a few patients in the follow-up pe-
riod.
We included the pre-STCS case series because of the low
number of PTLD patients in the STCS cohort.
Only patients aged ≥18 years old at the time of transplanta-
tion and undergoing SOT from 1986 met the inclusion cri-
teria for this study.
PTLD was defined as lymphoproliferative disorder devel-
oping at least 1 month after transplantation and no later
than 2 years after loss of graft function [17].
For each transplant recipient, pre-STCS or STCS, data in-
cluded demographic characteristics, serology results for
EBV (EBV IgG) and cytomegalovirus (CMV IgG). In-
formation on the initial immunosuppressive regimen pre-
scribed prior to hospital discharge, 6 and 12 months after
the solid organ transplant, and at the time of the PTLD di-
agnosis were also obtained.
Transplant centres reported on the occurrence of PTLD
during follow-up, which were categorised according to the
2008 WHO classification. PTLDs diagnosed within 1 year
of transplant were defined as early-onset PTLD and those
diagnosed after 1 year were defined as late-onset PTLD.
Clinical data
All patients with PTLD were staged retrospectively ac-
cording to the Ann Arbor staging system, and International
Prognostic Index (IPI) [18] scores were calculated wher-
ever possible. Performance status and response to treat-
ment were determined retrospectively and were extracted
from clinical reports. Approval for the study was obtained
from the institutional review boards of all five participating
transplant centres.
Morphological classification
Owing to the retrospective nature of the study, with cases
of PTLD diagnosed back to 1990, it was not possible to do
a central review of the pathology. PTLDs were categorised
according to the 2008 WHO classification, with informa-
tion retrieved from charts.
Histological detection of EBV
EBV was identified in PTLD tissue specimens by in-situ
hybridisation for EBV (EBER; Epstein-Barr virus encoded
RNA). This information was retrieved from charts.
Statistical analysis
Overall survival was estimated using the Kaplan-Meier
method, and was determined from the date of PTLD diag-
nosis to the date of death from any cause or last follow-up.
A p-value <0.05 was considered statistically significant,
and all p-values were two-sided. The survival analysis ac-
counted for loss to follow up, graft loss and the varying ob-
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servation time of each patient. No fixed denominator was
applied.
Results
During the pre-STCS period 8708 solid organ transplants
were performed nationwide [19] and 2942 were performed
during the STCS period. After exclusion of patients
younger than 18 years, 79 patients were diagnosed with
PTLD in five transplant centres in Switzerland. In total, 62
patients undergoing solid organ transplantation in January
1986 or later and having a diagnosis of PTLD up to April
2008 were included in the pre-STCS case series. Seventeen
patients were included in the STCS cohort with a solid or-
gan transplant not before May 2008 and a PTLD diagnosed
by December 2014. The interval between transplantation
and PTLD occurrence ranged between 2 and 281 months
(table 1) and some patients of the pre-STCS case series
were diagnosed with PTLD during the period of the STCS
cohort. The observation period of the two cohorts ended in
December 2014.
Basic characteristics
The baseline characteristics of PTLD patients are present-
ed in table 2. The median age of patients at transplantation
was similar in both cohorts, namely 43 years (range 18–69)
in the pre-STCS case series and 44 years (18–61) years in
the STCS. Our data showed a strong male predominance
in both cohorts, in accordance with the gender distribution
of transplanted patients in the STCS, with 63.2% male pa-
tients [20].
Cumulative incidence of PTLD among SOT patients
After 1 year, 0.22% (95% confidence interval [CI]
0.09–0.53%) of STCS patients were diagnosed with PTLD
and at 5 years 0.96% (95% CI 0.52–1.80%, fig. 1) were di-
agnosed.
For the pre-STCS case series, the exact number of trans-
planted patients and their survival is unknown since not all
cases were recorded. Therefore, we do not know the inci-
dence rate of PTLD for this cohort, nor any effects of po-
tential risk factors. For the STCS cohort, it was not pos-
sible to calculate the incidence rate because of the low
number of cases.
Morphological classification and localisation of PTLD
In both cohorts the majority of cases were monomorphic
(76% for pre-STCS and 59% for the STCS) or polymor-
phic (13% for pre-STCS and 41% for the STCS) subtypes
(table 2). The high variability may be in part explained
by underreporting of early stage PTLD that resolves with
reduction of immunosuppression alone [21]. Seventy-nine
percent of the monomorphic PTLDs were diffuse large B-
cell lymphoma (DLBCL) in the pre-STCS case-series and
69% for the STCS.
Epstein-Barr virus serostatus and status of PTLD tis-
sue
The EBV serostatus D/R (donor/recipient) in the STCS pe-
riod was known in only 13/17 patients, and was D+/R+
in 11 patients and D+/R− in 2 cases. Sufficient PTLD tis-
sue was available for analysis of EBV status (by means
of EBER in situ hybridisation) in 68 cases of both cohorts
(table 2). For early-onset PTLDs (PTLD diagnosed before
1 year after the transplant), 100% were EBV positive in the
pre-STCS case series and 86% in the STCS (table 3). For
late-onset PTLDs (PTLD diagnosed more than 1 year af-
ter the transplant) at least 34% of patients with an identi-
fiable EBV status were EBV positive in the pre-STCS and
at least 80% for STCS patients (table 3).
Different characteristics and outcome of early versus
late onset PTLD
Early onset PTLD more often involved the transplanted or-
gan (in 33% of early onset PTLDs for the pre-STCS and in
57% of early PTLD for the STCS, table 3) and were more
often associated with the use of calcineurin inhibitors such
as ciclosporin and tacrolimus (in 100% of early PTLD for
the pre-STCS and in 72% of early PTLD for the STCS).
Figure 1: Post-transplant lymphoproliferative disorder cumulative
incidence rate according to time after transplantation for solid or-
gan transplant patients in the Swiss Transplant Cohort Study.
Table 1: Time from transplantation to post-transplant lymphoproliferative disorders (PTLD) diagnosis (months) with histological substratification.
WHO Classification of PTLD Pre-STCS STCS Pre-STCS+STCS
Median 75 No case 75Early
Range 64–85 No case 64–85
Median 14 10 13Polymorphic
Range 5–237 2–28 2–237
Median 96 17 81Monomorphic
Range 3–281 3–59 3–281
Median 67 No case 67Hodgkin's
Range 26–228 No case 26–228
Median 90 14 59All histologies
Range 3–281 2–59 2–281
STCS = Swiss Transplant Cohort Study
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Table 2: Basic demographic characteristics.
Pre-STCS
(n = 62)
STCS
(n = 17)
Characteristics
No. % No. %
Male 51 82 11 65Sex
Female 11 18 6 35
Median 43 – 44 –
Average 43 – 46 –
Range 18–69 – 18–61 –
18–35 18 29 4 24
36–53 30 48 6 35
Age at first transplantation, years
>53 14 23 7 41
Kidney 38 61 6 35
Heart 9 15 2 12
Lung 5 8 6 35
Liver 8 13 1 6
Pancreas + kidney 1 2 1 6
Liver + kidney 0 0 0 0
Heart + kidney 1 2 0 0
Organ transplanted
Bowel and pancreas 0 0 1 6
Early 2 3 0 0
Polymorphic 8 13 7 41
Monomorphic (all) 47 76 10 59
Monomorphic DLBCL 37 60 7 41
Monomorphic Burkitt lymphoma 4 6 0 0
Monomorphic other 6 10 0 0
Histology
Hodgkin’s disease 5 8 0 0
Median 53 – 45 –
Mean 51 – 48 –
Range 22–75 – 18–65 –
18–35 9 15 3 18
36–53 22 35 7 41
Age at PTLD diagnosis, years
>53 31 50 7 41
Within 1 year after transplant 9 15 8 47Time of onset of PTLD
More than 1 year after transplant 53 85 9 53
Stage I–II 30 48 11 65Ann Arbor stage
Stage III–IV 32 52 6 35
0–2 36 58 12 71
3–5 20 32 5 29
IPI
Insufficient data 6 10 0 0
Positive (EBV IgG or PCR) 25 40 11 65
Negative (EBV IgG or PCR) 5 8 4 24
EBV serostatus before transplant patient
Insufficient data 32 52 2 12
Positive 36 58 16 94
Negative 9 15 0 0
EBV serostatus before PTLD diagnosis, pa-
tient
Insufficient data 17 27 1 6
Positive 27 44 14 82
Negative 26 42 1 6
Tumour EBV status
Insufficient data 9 15 2 12
CYA ±– AZA 35 56 6 35
TAC + other 11 18 9 53
AZA without CYA 0 0 0 0
Steroids 0 0 2 12
Other 2 3 0 0
Initial maintenance immunosuppression at
transplantation
NA 14 23 0 0
CYA ± AZA 32 52 6 35
TAC + other 15 24 9 53
AZA without CYA 2 3 1 6
Steroids 4 6 1 6
Other 2 3 0 0
Maintenance immunosuppression at the
time of the PTLD diagnosis
NA 7 11 0 0
Median 63 – 63 –
Mean 59 – 57 –
Age at death, years
Range 24–82 – 42–66 –
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Pre-STCS
(n = 62)
STCS
(n = 17)
Characteristics
No. % No. %
Median 141 – 33 –
Mean 151 – 37 –
Follow up duration on months since trans-
plantation
Range 19–283 – 6–63 –
AZA without CYA = azathioprine without ciclosporin; CYA ± AZA = ciclosporin with or without azathioprine; DLBCL = diffuse large B-cell lymphoma; EBV = Epstein-Barr virus; IPI
= International Prognostic Index; NA = not available; PCR = polymerase chain reaction; PTLD = post-transplant lymphoproliferative disorder; STCS = Swiss Transplant Cohort
Study; TAC + other = tacrolimus with other immunosuppression
In both early and late onset, monomorphic subtypes were
most common, but in the early-onset PTLD the proportion
of polymorphic subtypes was higher than in late onset
PTLDs in the pre-STCS case series (table 3).
In the pre-STCS case series, median survival was shorter
in patients with early-onset PTLD (38 months) than in pa-
tients with late onset PTLD (63 months), in contrast to the
STCS cohort where they were about equal (table 3). How-
ever, the follow-up for the STCS cohort was significantly
shorter (table 2). Despite incomplete data for the pre-STCS
cohort, the percentage of patients who had died at the end
of the follow up was 17% for patients with early-onset
PTLD and 22% for patients with late-onset PTLD, which
was not notably different (table 3). Furthermore, owing to
shorter follow-up of STCS- patients and the low number or
patients, survival in early and late onset PTLD cannot be
compared with pre-STCS-patients.
Immunosuppressive drugs at time of transplantation
and at time of PTLD occurrence
Data of induction immunosuppression at time of transplan-
tation was reported only for STCS patients. In this cohort,
11 patients (65%) received basiliximab, 4 patients (23%)
received antithymocyte globulin (ATG), 1 patient (6%) re-
ceived ATG and intravenous immunoglobulin (IVIG) and
1 patient (6%) received basiliximab and ATG.
Initial maintenance immunosuppression at the time of
transplantation included a calcineurin inhibitor (ci-
closporin and tacrolimus) for at least 74% of the pre-STCS
case series and in 88% of the STCS patients (table 2).
At the time of PTLD occurrence, 76% of patients of the
pre-STCS case series and 88% of the patients of the STCS
were on calcineurin inhibitors (table 2).
Outcome
For the pre-STCS case series, the median follow-up after
PTLD diagnosis was 141 months with a range of 19 to 283
months (table 2). This follow-up continued even during
the STCS period. However, the median follow-up for the
Table 3: Early versus late onset post-transplant lymphoproliferative disorder (PTLD).
Cohort Pre-STCS STCS
Onset of PTLD Early Late Early Late
Absolute no. % of early Absolute no. % of late Absolute no. % of early Absolute no. % of late
Total 9 15 53 85 7 41 10 59
PTLD in organ transplant 3 33 3 6 4 57 2 20
CYA ± AZA 7 78 25 47 3 43 3 30
TAC + other 2 22 13 25 2 29 7 70
AZA without
CYA
0 0 2 4 1 14 0 0
Steroids 0 0 4 8 1 14 0 0
Other 0 0 2 4 0 0 0 0
Immunosuppressant
at PTLD diagnosis
NA 0 0 7 13 0 0 0 0
Early 0 0 2 4 0 0 0 0
Polymorphic 3 33 4 8 3 43 4 40
Monomorphic 6 67 42 79 4 57 6 60
Histology subtype
Hodgkin’s dis-
ease
0 0 5 9 0 0 0 0
Median 38 – 63 – 63 – 62 –
Mean 38 – 61 – 58 – 58 –
Latency PTLD diag-
nosis to death in
months
Range 24–51 – 36–82 – 42–64 – 43–66 –
Median 83 – 150 – 23 – 47 –
Mean 97 – 160 – 25 – 46 –
Total duration of fol-
low up since TPL in
months
Range 19–189 – 20–310 – 6–59 – 30–63 –
Dead 2 22 9 17 4 57 3 30
Alive 5 56 26 49 0 0 1 10
Outcome at the end
of the follow up
NA 2 22 18 34 3 43 6 60
Positive 9 100 18 34 6 86 8 80
Negative 0 0 26 49 0 0 1 10
Tumour EBV status
Insufficient da-
ta
0 0 9 17 1 14 1 10
AZA without CYA = azathioprine without ciclosporin; CYA ± AZA = ciclosporin with or without azathioprine; DLBCL = diffuse large B-cell lymphoma; EBV = Epstein-Barr virus NA
= not available; STCS = Swiss Transplant Cohort Study; TAC + other = tacrolimus with other immunosuppression; TPL = transplantation
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STCS cohort starting in May 2008, was only of 33 months
(range 6–63).
The overall survival rates at 1, 5 and 10 years after di-
agnosis were of 80% (95% CI 68–87%), 56% (95% CI
42–68%) and 51% (95% CI 37–63%), respectively, for the
two cohorts (fig. 2). However, the median age at death
was similar, 63 years, for the pre-STCS and STCS cohorts
(table 2).
There was no censoring at any time and no loss to follow
up. We did not censor any graft loss patient.
Discussion
In this study, we found for the STCS cohort (between 2008
and 2014) a low cumulative incidence of PTLD in Switzer-
land, with only 0.96% at 5 years, irrespective of the type
of organ that was transplanted. Our findings are at variance
with other studies that have described higher cumulative
incidences of PTLD, as quoted in numerous national trials
and large cohorts.
In a population-based cohort study in Denmark between
1990 and 2011, Maksten et al. found a cumulative inci-
dence of 1.4% at 5 years in renal transplants [17]. How-
ever, this study differed from ours by including young pa-
tients, with 17.1% being less than 17 years old. Paediatric
patients are known to have a higher incidence of PTLD,
because of the higher rate of EBV seronegativity in this
population [22]. This could partly explain the difference of
cumulative incidence between studies. In another study in-
cluding 1,206 recipients of liver transplants between 1985
and 2004 at a single institution, 37 recipients developed
a PTLD and Kremers et al. found a cumulative incidence
of 2.1% at 5 years [23]. In contrast, the STCS surprising-
ly has only 1 liver recipient with PTLD, possibly owing to
late onset PTLD after liver transplants and shorter follow-
up of the SCTS cohort. Moreover, in the Kremers study, 16
and 32% of the patients were treated with the monoclonal
antibody muromonab OKT3 and with high-dose steroids,
which is known to be a significant risk factor for the de-
velopment of PTLD. In a retrospective analysis between
1991 and 2011, Kremer et al. found a 5-year cumulative
incidence of PTLD of 5.9% in lung transplant recipients
[24]. They observed that the PTLD incidence decreased
between 1991 and 2011: Between 2001 and 2011, the an-
nual incidence of PTLD after transplantation ranged from
Figure 2: Overall Survival from post-transplant lymphoproliferative
disorder diagnosis for both cohorts combined.
0 to 3%. A decrease of PTLD incidence over time, which
could at least in part explain the low cumulative incidence
of PTLD in our study, was also observed by Kumarasinghe
et al. in a retrospective study between 1984 and 2013 in-
cluding 70 heart and lung recipients [25]. It is noteworthy
that the incidence of PTLD tends to be higher in thoracic
organ transplant recipients who have long-term profound
immunosuppression required to prevent the more serious
consequences of transplant rejection. In the thoracic organ
transplant cohort of Kumarasinghe et al., the incidence of
PTLD was 7.2% between 1984 and 1990 but only 1.99%
between 2006 and 2010. This decrease was attributed to
changing induction immunosuppression protocols, particu-
larly avoiding T cell-depleting therapy (i.e., ATG).
The relationship between maintenance therapy and PTLD
remains a matter of debate in the literature [26–28]. In
our study, as maintenance immunosuppression at the time
of transplantation, 74% of the pre-STCS case-series and
88% of the STCS patients were receiving calcineurin in-
hibitors (ciclosporin and tacrolimus) and 76% and 88%, re-
spectively, at the time of PTLD diagnosis (table 2). More-
over, the agents used for maintenance immunosuppression
have changed over time (for instance, using tacrolimus in-
stead of ciclosporin), had a heterogeneous pattern reflect-
ing among other factors the different organs transplanted,
and the intensity of the immunosuppression could not be
reported reliably in the retrospective setting. Consequently,
we could not identify significantly the correlation between
the type of maintenance and the development of PTLD.
The low cumulative incidence at 5 years might as well
reflect the efforts made to minimise the number of EBV
negative recipients with EBV donors. According to the
study directed by Walker et al. [29], the incidence rate of
PTLD for EBV-seronegative recipients is 24 times higher
than in EBV-seropositive recipients. In our patients, the in-
terpretation of the EBV serology status was not possible
in the pre-STCS case-series, due to incomplete data. The
STCS cohort included in total 2,621 patients with a SOT
in the period of time studied. But only 13 patients with
a PTLD met the inclusion criteria. Those 13 PTLD cas-
es had either a positive-positive or negative-positive recip-
ient/donor EBV status, which emphasised the importance
in prevention of screening and matching correctly the EBV
status, which can be a difficult or impossible task if there
is a scarcity of organ donors.
As final comment regarding the low cumulative incidence
of PTLD at 5 years in the STCS cohort, it is unclear if the
cumulative incidence for the same cohort is also lower at
10 years, or even later. Indeed, the median follow-up af-
ter transplantation was only 33 months in the STCS co-
hort (table 1), which is a limitation. According the data of
Maksten et al., the incidence of PTLD after kidney trans-
plantation changed over time, showing a bimodal pattern
with highest incidence rates in the first year and more than
10 years after transplantation [17]. Nevertheless, the inci-
dence of PTLD differs with the organ transplanted. Ac-
cording to Kumarasinghe et al., the median time from heart
and lung transplantation to PTLD diagnosis is only 3.2
years, probably due to higher immunosuppression required
for transplanted thoracic organs [25].
Interestingly, the comparison of the two cohorts show that
the median age at transplantation and the median age at
death are almost the same. In contrast, the median age at
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PTLD diagnosis was 53 years for the patients of the pre-
STCS and 45 years for the patients of the STCS cohort
(table 2). We speculate that earlier detection of the PTLD
could be attributed to a better awareness and better clinical
and radiological screening for PTLD among SOT patients.
Furthermore, many transplant centres have incorporated
EBV monitoring into the routine follow-up evaluation of
patients at high risk for PTLD [30]. However, this differ-
ence of age at the time of PTLD diagnosis could be in part
the result of underreporting of early PTLD disorders that
can be treated with reduction of immunosuppression only
in the pre-STCS case series.
The 5-year overall survival of the pre-STCS and STCS
combined was 56%, which is superior to the 48% reported
in an Irish retrospective study between 1991 and 2010 of
kidney transplant recipient patients with a PTLD diagno-
sis [31]. Unfortunately, our study did not have enough pa-
tients either for a statistical evaluation of mortality or to
explain why a group of patients diagnosed earlier with a
PTLD presents a similar median age at death as a group of
patients diagnosed later. If the median age of death is the
same, the cause of death was probably different. Putative-
ly, some deaths were not related to the PTLD diagnosis but
to other causes, such as infections. This aspect could not be
elucidated in this study.
This study had strengths. Firstly, it was a nationwide co-
hort study of PTLD in Switzerland. Secondly, our patient
series was considerable, including 79 cases of PTLD.
Thirdly, our follow-up was extensive for the pre-STCS
case-series with a median of 11.6 years.
In conclusion, we found at 5 years a cumulative incidence
of PTLD, disregarding any type of organ transplanted, of
only 0.96% between 2008 and 2014 in Switzerland, which
is lower than described in the literature. We speculate that
reduction of the risk factors such as notably reducing the
recipient/donor EBV mismatch by allocating EBV nega-
tive transplants to EBV negative recipients and the usage
of less T cell immunosuppression led to those results. Sec-
ondly, the two successive cohorts show that PTLD tends
to be diagnosed earlier, possibly owing to a better identi-
fication of the disease. However, the median age at death
stayed the same. The causes of death and the reason for
the decline in incidence of PTLD over time could not be
clarified by this study. Open questions need to be answered
with further studies of larger cohorts to improve our under-
standing of PTLD occurrence and development in trans-
plant patients.
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